Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash & Equivalents (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash & Equivalents for 12 consecutive years, with $174.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 647.6% to $174.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $174.8 million, a 647.6% increase, with the full-year FY2024 number at $37.8 million, changed N/A from a year prior.
  • Cash & Equivalents was $174.8 million for Q3 2025 at Theravance Biopharma, down from $281.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $418.5 million in Q3 2022 to a low of $23.4 million in Q3 2024.
  • A 5-year average of $143.1 million and a median of $110.6 million in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 82.87% in 2023, then soared 647.6% in 2025.
  • Theravance Biopharma's Cash & Equivalents stood at $121.4 million in 2021, then skyrocketed by 145.56% to $298.2 million in 2022, then plummeted by 75.96% to $71.7 million in 2023, then tumbled by 47.27% to $37.8 million in 2024, then surged by 362.4% to $174.8 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Cash & Equivalents are $174.8 million (Q3 2025), $281.9 million (Q2 2025), and $110.6 million (Q1 2025).